A carregar...
Novel agents that downregulate EGFR, HER2, and HER3 in parallel
EGFR, HER2, and HER3 contribute to the initiation and progression of human cancers, and are therapeutic targets for monoclonal antibodies and tyrosine kinase inhibitors. An important source of resistance to these agents arises from functional redundancy among EGFR, HER2, and HER3. EGFR family member...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4496366/ https://ncbi.nlm.nih.gov/pubmed/25865227 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|